Trial · NCT03395184
Results by group124
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 124
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12: Induction Period | Induction Period: Placebo QD | 12.8 | 90% Confidence Interval 7.1 to 19.9 | Percentage of participants | |
| Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12: Induction Period | Induction Period: Ritlecitinib 200 mg/50 mg QD | 27.2 | 90% Confidence Interval 19.6 to 35.7 | Percentage of participants | |
| Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12: Induction Period | Induction Period: Brepocitinib 60 mg QD | 33.8 | 90% Confidence Interval 25.1 to 43.1 | Percentage of participants | |
| Number of Participants With Laboratory Test Abnormalities During OLE Period | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | 33 | Participants | ||
| Number of Participants With Laboratory Test Abnormalities During OLE Period | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | 76 | Participants | ||
| Number of Participants With Laboratory Test Abnormalities During OLE Period | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | 26 | Participants | ||
| Number of Participants With Laboratory Test Abnormalities During OLE Period | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD | 56 | Participants | ||
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | DBP; value < 50 (mmHg) | 0 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | DBP; value < 50 (mmHg) | 2 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | DBP; value < 50 (mmHg) | 0 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD | DBP; value < 50 (mmHg) | 1 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | DBP; change >=20 (mmHg) increase | 4 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | DBP; change >=20 (mmHg) increase | 6 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | DBP; change >=20 (mmHg) increase | 2 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD | DBP; change >=20 (mmHg) increase | 6 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | DBP; change >=20 (mmHg) decrease | 1 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | DBP; change >=20 (mmHg) decrease | 4 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | DBP; change >=20 (mmHg) decrease | 3 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD | DBP; change >=20 (mmHg) decrease | 8 | Participants | |
| Number of Participants According to Categorization of Vital Signs During OLE Period | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | PR; value > 120 (bpm) | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03395184/results